Article Text
PDF
Abstract
Introduction/Background To evaluate the main risk factors for recurrence in endometrial cancer and to assess the prognostic impact of treatment strategies in this setting.
Methodology We performed a single institutional retrospective study of women with endometrial cancer who underwent surgical treatment between January 2007 and December 2019. We analyzed the pattern of tumor recurrence, the main histological risk factors related to disease-free and overall and its relation to the recurrence treatment received. Kaplan-Meier curves were used to estimate survivals.
Results A total of 351 patients underwent surgery and were followed up during a mean±SD time of 82±47 months. 68 (18.6%) patients relapsed during the follow up. Isolated pelvic recurrence occurred in 20 (29.4%) patients and distant recurrence in 48 (70.6%) patients. The main pathological characteristics associated to a significant increased risk of recurrence were the extensive lymphovascular space invasion, tumoral grade and histological type (Figures 1–3). Among patients who relapsed, 22 (32%) patients underwent surgery, 35 (51.1%) patients received systemic treatment and 11 (16.2%) patients palliative care. In patients with local recurrence, 12( 60%) patients were treated with surgery, 5 (25%) with systemic treatment and 3 (15%) with palliative care. Treatment strategy received had an impact on overall survival showing better results in patients who underwent surgery (figure 4). Patients with local recurrence who were not candidates for surgery had unresectable criteria such as extensive pelvic wall involvement in most of cases. Patients referred to palliative care were most likely to be in poor general condition and to have disseminated disease.
Conclusion Patients with local recurrences had a better survival rates when treated by surgical cytoreduction. It seems to be especially important to perform an appropriate and an individualized patient selection in order to obtain the biggest benefit from surgery when presented a relapse of the disease.
Disclosures We have no disclosures.
